Glenmark launches Covid-19 drug at Rs 103 per tablet – Favipiravir

This post has already been read 36 times!

The COVID-19 drug will be available as a 200 mg tablet at a maximum retail price (MRP) of Rs 3,500 for a strip of 34 tablets, Glenmark Pharmaceuticals said.

Drug firm Glenmark Pharmaceuticals on Saturday said it has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate Covid-19 at a price of about Rs 103 per tablet.

FabiFlu is the first oral favipiravir-approved medication in India for the treatment of Covid-19.

It is a prescription-based medication, with recommended dose being 1,800 mg twice daily on day one, followed by 800 mg twice daily up to day 14, the drug firm said.

When asked about the company’s manufacturing capacity of the drug, the drug firm said: “Considering a minimum of two strips per patient, Glenmark will be able to provide FabiFlu for about 82,500 patients in the 1st month itself. We will be closely monitoring the evolving situation and basis of the situation, we will work to scale and meet the healthcare needs of the country”.

The company is producing the active pharmaceutical ingredients (API) for the product at its Ankleshwar plant, while the formulation is being manufactured at its Baddi plant.

The drug will be available both through hospitals and the retail channel, Glenmark said.